About Celltrion
Celltrion is a company based in Incheon (South Korea) founded in 2002. The company has 2,900 employees as of December 31, 2024. Celltrion has completed 1 acquisition, including iQone Healthcare Group. Celltrion offers products and services including Biosimilars and R&D Services.
- Headquarter Incheon, South Korea
- Employees 2900 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Celltrion, Inc.
-
Annual Revenue
$2.41 B (USD)63.45as on Dec 31, 2024
-
Net Profit
$286.61 M (USD)-21.09as on Dec 31, 2024
-
EBITDA
$617.22 M (USD)1.47as on Dec 31, 2024
-
Latest Funding Round
- Investors
-
Employee Count
2900
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Celltrion
Celltrion is a publicly listed company on the KRX with ticker symbol 068270 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Celltrion
Celltrion offers a comprehensive portfolio of products and services, including Biosimilars and R&D Services.
Biosimilars are developed and manufactured for various therapeutic areas such as immunology and oncology.
R&D services are provided for biopharmaceutical development, including clinical trials and regulatory affairs.
Funding Insights of Celltrion
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2010 | Amount | Post-IPO - Celltrion | Valuation |
investors |
Investors in Celltrion
Celltrion has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Temasek.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
An investment platform is provided for diverse sectors and geographies.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Celltrion
Celltrion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include iQone Healthcare Group.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provider of biosimilar and breakthrough medicines distribution
|
1979 |
Financial Statements - Celltrion
Celltrion Comparisons
Competitors of Celltrion
Frequently Asked Questions about Celltrion
Celltrion was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Celltrion is headquartered in Incheon, South Korea.
Woo-Sung Kee is the current CEO of Celltrion.
As of Dec 31, 2024, the latest employee count at Celltrion is 2,900.
Annual revenue of Celltrion is $2.41B as on Dec 31, 2024.
Founded in 2002 in Incheon, South Korea, the company operates in the biotechnology sector, focusing on antibody biosimilars. Rensima, a biosimilar to infliximab, is utilized for treating rheumatoid arthritis and other autoimmune conditions. Additional biosimilars in development include versions of rituximab, adalimumab, bevacizumab, palivizumab, cetuximab, and etanercept. In 2020, annual revenues of 1.6 billion and net profit of 433.3 million were recorded.
Celltrion offers Biosimilars and R&D Services.
Yes, Celltrion is publicly traded on KRX under the ticker symbol 068270.
Celltrion has made 1 acquisition, including iQone Healthcare Group.
Celltrion has 1 investor. Key investors include Temasek.
The ticker symbol of Celltrion is 068270 on KRX.